The U.S. Supreme Court got IP litigators fired up when it delivered a patent win for Teva Pharmaceuticals USA Inc. on Tuesday. But Teva had far less luck in a separate high court challenge, failing to persuade the justices to hear a key appeal over when federal law preempts patient lawsuits against generic drug companies.
The high court denied cert Tuesday in Teva v. Superior Court of California, Orange County, rebuffing a petition filed by Jay Lefkowitz of Kirkland & Ellis. Teva had asked the justices in February to review a California state court ruling allowing patients to proceed with claims that Teva and other companies failed to warn about dangers associated with its version of the osteoporosis drug Fosamax.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
